In a report released on January 5, Marie Thibault from BTIG maintained a Buy rating on Inari Medical (NARI – Research Report), with a price target of $93.00. The company’s shares closed last Friday at $64.05.
According to TipRanks, Thibault is an analyst with an average return of -2.2% and a 35.66% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Inari Medical, Atricure, and Insulet.
In addition to BTIG, Inari Medical also received a Buy from Piper Sandler’s Adam Maeder in a report issued on January 5. However, on December 22, Truist Financial maintained a Hold rating on Inari Medical (NASDAQ: NARI).
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $71.85 and a one-year low of $47.81. Currently, Inari Medical has an average volume of 791.8K.
Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is neutral on the stock. Last month, Hoffman William, a Director at NARI bought 103,492.00 shares for a total of $43,466.64.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inari Medical (NARI) Company Description:
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States.
Read More on NARI:
- Inari Medical price target raised to $70 from $65 at Truist
- Inari Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Inari Medical management to meet virtually with BTIG
- Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)
- Inari Medical announces first patient enrolled in PEERLESS II study
